Literature DB >> 26153496

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

H Yoshioka1, K Azuma2, N Yamamoto3, T Takahashi4, M Nishio5, N Katakami6, M J Ahn7, T Hirashima8, M Maemondo9, S W Kim10, M Kurosaki11, S Akinaga11, K Park7, C M Tsai12, T Tamura13, T Mitsudomi14, K Nakagawa15.   

Abstract

BACKGROUND: A previous randomized phase II study demonstrated that the addition of a c-Met inhibitor tivantinib to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib might prolong progression-free survival (PFS) in patients with previously treated, nonsquamous nonsmall-cell lung cancer (NSCLC). On a subset analysis, the survival benefit was greater in patients with wild-type EGFR (WT-EGFR) than in those with activating EGFR mutations. Herein, this phase III study compared overall survival (OS) between Asian nonsquamous NSCLC patients with WT-EGFR who received erlotinib plus tivantinib (tivantinib group) or erlotinib plus placebo (placebo group).
METHODS: A total of 460 NSCLC patients were planned to be randomized to the tivantinib or placebo group. Primary end point was OS. Secondary end points were PFS, tumor response, and safety. Tissue was collected for biomarker analysis, including c-Met and HGF expression.
RESULTS: Enrollment was stopped when 307 patients were randomized, following the Safety Review Committee's recommendation based on an imbalance in the interstitial lung disease (ILD) incidence between the groups. ILD developed in 14 patients (3 deaths) and 6 patients (0 deaths) in the tivantinib and the placebo groups, respectively. In the enrolled patients, median OS was 12.7 and 11.1 months in the tivantinib and the placebo groups, respectively [hazard ratio (HR) = 0.891, P = 0.427]. Median PFS was 2.9 and 2.0 months in the tivantinib and the placebo groups, respectively (HR = 0.719, P = 0.019). The commonly observed grade ≥ 3 adverse events in the tivantinib group were neutropenia (24.3%), leukopenia (18.4%), febrile neutropenia (13.8%), and anemia (13.2%).
CONCLUSIONS: This study was prematurely terminated due to the increased ILD incidence in the tivantinib group. Although this study lacked statistical power because of the premature termination and did not demonstrate an improvement in OS, our results suggest that tivantinib plus erlotinib might improve PFS than erlotinib alone in nonsquamous NSCLC patients with WT-EGFR. TRIAL REGISTRATION NUMBER: NCT01377376.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  c-Met inhibitor; erlotinib; nonsmall-cell lung cancer; phase III study; tivantinib

Mesh:

Substances:

Year:  2015        PMID: 26153496     DOI: 10.1093/annonc/mdv288

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  44 in total

1.  MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Authors:  Thanyanan Reungwetwattana; Sai-Hong Ignatius Ou
Journal:  Transl Lung Cancer Res       Date:  2015-12

2.  Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine.

Authors:  Vincenzo Di Noia; Ettore D'Argento; Sara Pilotto; Miriam Grazia Ferrara; Michele Milella; Giampaolo Tortora; Emilio Bria
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 3.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

4.  A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.

Authors:  Christos E Kyriakopoulos; Amy M Braden; Jill M Kolesar; Jens C Eickhoff; Howard H Bailey; Jennifer Heideman; Glenn Liu; Kari B Wisinski
Journal:  Invest New Drugs       Date:  2016-12-21       Impact factor: 3.850

Review 5.  Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Authors:  Alexander Drilon; Federico Cappuzzo; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2016-10-26       Impact factor: 15.609

Review 6.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

Review 7.  Effective implementation of novel MET pharmacodynamic assays in translational studies.

Authors:  Apurva K Srivastava; Tony Navas; William G Herrick; Melinda G Hollingshead; Donald P Bottaro; James H Doroshow; Ralph E Parchment
Journal:  Ann Transl Med       Date:  2017-01

8.  Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer.

Authors:  Nagio Takigawa; Nobuaki Ochi; Hiromichi Yamane
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 9.  Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.

Authors:  V Finisguerra; H Prenen; M Mazzone
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

10.  Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.

Authors:  Xian Sun; Chia-Wei Li; Wei-Jan Wang; Mei-Kuang Chen; Hui Li; Yun-Ju Lai; Jennifer L Hsu; Paul B Koller; Li-Chuan Chan; Pei-Chih Lee; Fang-Ju Cheng; Clinton Yam; Gong-Yan Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.